Regulus Therapeutics Inc
NASDAQ:RGLS 2:58:56 PM EDT
| Market Cap (Intraday) | 64.82M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.10 |
| 50-Day MA | $1.42 |
| 200-Day MA | $1.01 |
Regulus Therapeutics Inc Stock, NASDAQ:RGLS
4224 Campus Point Court, Suite 210, San Diego, California 92121
United States of America
Phone: +1.858.202.6300
Number of Employees: 24
Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.